Literature DB >> 20522009

alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.

Gianfranco Bazzu1, Giammario Calia, Giulia Puggioni, Ylenia Spissu, Gaia Rocchitta, Patrizia Debetto, Jessica Grigoletto, Morena Zusso, Rossana Migheli, Pier Andrea Serra, Maria Speranza Desole, Egidio Miele.   

Abstract

The classical animal models of Parkinson's disease (PD) rely on the use of neurotoxins, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine and, more recently, the agricultural chemicals paraquat and rotenone, to deplete dopamine (DA). These neurotoxins elicit motor deficits in different animal species although MPTP fails to induce a significant dopaminergic neurodegeneration in rats. In the attempt to better reproduce the key features of PD, in particular the progressive nature of neurodegeneration, alternative PD models have been developed, based on the genetic and neuropathological links between -synuclein ( -syn) and PD. In vivo microdialysis was used to investigate extracellular striatal DA dynamics in MPTP- and -syn-generated rodent models of PD. Acute and sub-acute MPTP intoxication of mice both induce prolonged release of striatal DA. Such DA release may be considered the first step in MPTP-induced striatal DA depletion and nigral neuron death, mainly through reactive oxygen species generation. Although MPTP induces DA reduction, neurochemical and motor recovery starts immediately after the end of treatment, suggesting that compensatory mechanisms are activated. Thus, the MPTP mouse model of PD may be unsuitable for closely reproducing the features of the human disease and predicting potential long-term therapeutic effects, in terms of both striatal extracellular DA and behavioral outcome. In contrast, the -syn-generated rat model of PD does not suffer from a massive release of striatal DA during induction of the nigral lesion, but rather is characterized by a prolonged reduction in baseline DA and nicotine-induced increases in dialysate DA levels. These results are suggestive of a stable nigrostriatal lesion with a lack of dopaminergic neurochemical recovery. The -syn rat model thus reproduces the initial stage and slow development of PD, with a time-dependent impairment in motor function. This article will describe the above experimental PD models and demonstrate the utility of microdialysis for their characterization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20522009     DOI: 10.2174/187152710791556177

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  13 in total

1.  Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice.

Authors:  Haeman Jang; David Boltz; Jennifer McClaren; Amar K Pani; Michelle Smeyne; Ane Korff; Robert Webster; Richard Jay Smeyne
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

4.  Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice.

Authors:  Valeria Uribe; Bibiana K Y Wong; Rona K Graham; Corey L Cusack; Niels H Skotte; Mahmoud A Pouladi; Yuanyun Xie; Konstantin Feinberg; Yimiao Ou; Yingbin Ouyang; Yu Deng; Sonia Franciosi; Nagat Bissada; Amanda Spreeuw; Weining Zhang; Dagmar E Ehrnhoefer; Kuljeet Vaid; Freda D Miller; Mohanish Deshmukh; David Howland; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2012-01-18       Impact factor: 6.150

5.  Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease.

Authors:  Asya Ozkizilcik; Aruna Sharma; Dafin F Muresanu; José V Lafuente; Z Ryan Tian; Ranjana Patnaik; Herbert Mössler; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

6.  Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine.

Authors:  R Pattarini; Y Rong; K R Shepherd; Y Jiao; C Qu; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2012-04-24       Impact factor: 3.590

7.  Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease.

Authors:  Azizul Haque; Supriti Samantaray; Varduhi H Knaryan; Mollie Capone; Azim Hossain; Denise Matzelle; Raghavendar Chandran; Donald C Shields; Ariana Q Farrand; Heather A Boger; Naren L Banik
Journal:  Exp Neurol       Date:  2020-04-14       Impact factor: 5.330

8.  Neurological morphofunctional differentiation induced by REAC technology in PC12. A neuro protective model for Parkinson's disease.

Authors:  Margherita Maioli; Salvatore Rinaldi; Rossana Migheli; Gianfranco Pigliaru; Gaia Rocchitta; Sara Santaniello; Valentina Basoli; Alessandro Castagna; Vania Fontani; Carlo Ventura; Pier Andrea Serra
Journal:  Sci Rep       Date:  2015-05-15       Impact factor: 4.379

9.  Real-time electrochemical recording of dopamine release under optogenetic stimulation.

Authors:  Wen-Tai Chiu; Che-Ming Lin; Tien-Chun Tsai; Chun-Wei Wu; Ching-Lin Tsai; Sheng-Hsiang Lin; Jia-Jin Jason Chen
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

10.  Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.

Authors:  Michaeline L Hebron; Irina Lonskaya; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2013-05-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.